Iit may sound fine if the combination drugs become Schedule II like the DEA wants. Then they are on a more level playing field with Zohydro. Great for Zogenix. But the FDA has resisted this request in the past so that the drugs will be more available to patients. If they go along with the DEA this time it shows the FDA is succumbing to Government pressure to put public safety first with the needs of patients second. Not so good for Zohydro.